Chemdex
This article was originally published in The Gray Sheet
Executive Summary
Business-to-business life sciences e-commerce firm completes $1.3 bil. acquisition of medical device Web-based auction company Promedix, Chemdex says Feb. 11. Chemdex will exchange an estimated 12 mil. shares of its common stock for all outstanding Promedix shares, options and warrants under the purchase transaction. Promedix spins off specialty medical product distribution business, which is not part of the deal. Separately, Chemdex finalizes purchase of all shares, options and warrants of privately-held SpecialtyMD.com in exchange for 1.25 mil. shares of Chemdex common stock. At Chemdex' Feb. 10 closing value of 105-3/8, the transaction is valued at approximately $132 mil. SpecialtyMD.com offers clinical and product content to clinicians and purchasing professionals
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.